Breast cancer–related regulator of tp53

PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)

Retrieved on: 
Thursday, June 30, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, FDA, Annual report, Patient, Cholangiocarcinoma, Research, Pirfenidone, IPF, Vital capacity, PRTC, Trial of the century, Breast cancer, Ambrose, Colorectal cancer, Internal medicine, Company, Cancer, Disease, LSE, Food, Inflammation, AES, Leukemia, TID, Toxicity, Scar, Immune system, Prognosis, U.S. FDA, Idiopathic pulmonary fibrosis, Pharmacokinetics, Mab, Degenerative disease, Neoplasm, Therapy, FVC, Form 6-K, Environment, Private Securities Litigation Reform Act, University, Arm, Survival, Fibrosis, SEC, Risk, Immunoglobulin G, Drug development, PureTech Health, Safety, Twitter, Breast cancer–related regulator of tp53, Antacid, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Multimedia, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220630005245/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220630005245/en/
    PureTech announced the initiation of a late-stage clinical study of LYT-100 (deupirfenidone), PureTechs wholly-owned therapeutic candidate for the potential treatment of idiopathic pulmonary fibrosis (IPF).
  • (Graphic: Business Wire)
    The initiation of this study is supported by substantial clinical data demonstrating favorable safety and tolerability of LYT-100, said Julie Krop, M.D., Chief Medical Officer of PureTech.
  • We are excited to be taking this important step towards our goal of helping patients with this devastating condition.
  • The prognosis of IPF is poor, with the median survival after diagnosis generally estimated at two to five years.

PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications

Retrieved on: 
Tuesday, June 14, 2022
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Science, COVID-19, Clinical Trials, Hospital, IPF, Data, Death, PRTC, Șaeș, Fibrosis, Time, Pneumonia, Company, AES, COVID, Interstitial lung disease, Headache, Research, Keck School of Medicine of USC, Safety, Fatigue, Pirfenidone, LSE, Annual report, Degenerative disease, Long COVID, Nausea, Cancer, Inflammation, Environment, AE, Dizziness, Therapy, University, Daphne, Risk, FDA, Proning, COVID-19, Patient, Private Securities Litigation Reform Act, U.S. FDA, Medicine, Natural history, Incidence, Breast cancer–related regulator of tp53, SEC, Twitter, Population, Survivor, Drug development, Rash, Intention, Form 6-K, PureTech Health, Principal, Idiopathic pulmonary fibrosis, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced results from a Phase 2 study of LYT-100-COV (deupirfenidone) in patients with post-acute Long COVID with respiratory complications.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced results from a Phase 2 study of LYT-100-COV (deupirfenidone) in patients with post-acute Long COVID with respiratory complications.
  • The global, double-blind, randomized, placebo-controlled study is one of few to complete in patients with post-acute COVID.
  • The study enrolled 177 patients averaging 55 years of age who experienced continued respiratory complications following hospitalization for acute COVID-19 infection that required treatment with supplemental oxygen.
  • The primary efficacy endpoint was a three-month change from baseline compared to placebo on the six-minute walk test (6MWT) distance.

PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022

Retrieved on: 
Monday, May 16, 2022
Health, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Cancer, Physician, Inflammation, Pulmonary fibrosis, Company, PureTech Health, Ageing, Radiation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Food, International Conference on Cold Fusion, Survival, AES, Incidence, Idiopathic pulmonary fibrosis, AUC, Degenerative disease, Environment, Multimedia, Patient, Poster, LSE, Risk, Life expectancy, Form 6-K, Cmax, Pirfenidone, Research, Lymphedema, FDA, Breast cancer–related regulator of tp53, U.S. FDA, Fibrosis, Time, Conference, Compliance, Prognosis, Drug development, TID, Therapy, Twitter, American Thoracic Society, IPF, Fed, SEC, Diagnosis, COVID, PRTC, Innovation, Annual report, Pharmaceutical industry, Dietary supplement

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of additional data for PureTechs LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of additional data for PureTechs LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference.
  • Key outcomes of this study that are supportive of the observed improved tolerability of LYT-100 were reported in January 2022.
  • View the full release here: https://www.businesswire.com/news/home/20220516005130/en/
    PureTech today announced the presentation of additional data for PureTech's LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference.
  • PureTech also expects to initiate registration-enabling studies of LYT-100 in patients with IPF in the first half of 2022.

PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates

Retrieved on: 
Tuesday, November 16, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Pirfenidone, PK, AES, Safety, Nausea, Drug development, Degenerative disease, COVID-19, Private Securities Litigation Reform Act, Fasting, Toxicity, LSE, Plasma, Kidney, BID, U.S. FDA, Pharmacology, Inflammation, Food, Multimedia, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PureTech Health, Annual report, Long COVID, Cancer, IPF, Twitter, Idiopathic pulmonary fibrosis, Breast cancer–related regulator of tp53, Headache, Fed, Company, Environment, PRTC, Therapy, Lymphedema, SEC, Innovation, Abdominal distension, Fibrosis, BIG, PACS, Biology, Patient, FDA, Axis, Brain, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20211116005332/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211116005332/en/
    Today PureTech announced that the results from a Phase 1 trial evaluating multiple ascending doses and the food effect of LYT-100 (deupirfenidone) were published in the journal Clinical Pharmacology in Drug Development.
  • Were encouraged by these results and look forward to the upcoming clinical readouts as we advance LYT-100 in multiple indications.
  • PureTech has also initiated additional Phase 1 clinical trials to further explore the PK, dosing and tolerability of LYT-100 in healthy volunteers.
  • Results from these trials are expected to provide additional supportive data to inform the clinical development of LYT-100 across multiple indications.

PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021

Retrieved on: 
Monday, August 23, 2021
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Lymphedema, Company, Cancer, Pharmacology, Twitter, Fibrosis, Therapy, PureTech Health, Interstitial lung disease, LSE, PK, Innovation, Fed, IPF, Research, Doctor of Philosophy, Breast cancer–related regulator of tp53, Degenerative disease, Fasting, Inflammation, Biology, Multimedia, Risk, Plasma, Safety, Patient, Environment, Idiopathic pulmonary fibrosis, PRTC, Long COVID, FDA, GI, Brain, Annual report, BIG, Axis, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20210823005064/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210823005064/en/
    PureTech Health today announced the presentation of the Phase 1 multiple ascending dose and food effect study of LYT-100 at the virtual European Respiratory Society International Congress.
  • The Phase 1 multiple ascending dose food and effect study was a randomized, double-blind, placebo-controlled study of LYT-100 in healthy volunteers in both fed and fasting states.
  • PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested.
  • PureTech has also initiated three additional Phase 1 clinical trials to explore further the PK, dosing and tolerability of LYT-100 in healthy volunteers.